ARCHIVES

FDA to refer false statements by regulated companies to SEC.

This article is from The Cancer Letter archive.

Vol. 30 No. 09 | February 27, 2004

Download PDF Visit The Full Archive

Related Articles

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

April 27, 2012

In Brief: Six On NCA Serve Out Terms, No Successors in Sights DCBD Renamed With ‘Centers’ In Title

February 9, 1990

Carroll Named Deputy Director At Huntsman; Pamer Leads Infectious Disease Service, MSKCC.

September 29, 2000

Modality Combo Decreases Prostate Cancer Recurrence

August 27, 2004

Pathology In Operating Suite Cuts Need for More Surgery

February 24, 2012

Men With PSA Of 7 Or Higher More Likely To Have Biopsy

February 25, 2005